KAHN BARBARA
Known title: DirectorCIK: 0001520391
Associated companies
Transaction History
| DXCM | ▼ Sell | Gift | 2,927 | $0 | 5/18/2024 | View on chart |
| DXCM | ▼ Sell | Gift | 2,927 | $0 | 5/18/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 2,927 | $3 | 5/18/2023 | View on chart |
| DXCM | ▼ Sell | Gift | 3,976 | $0 | 5/18/2023 | View on chart |
| DXCM | ▼ Sell | Gift | 3,976 | $0 | 5/18/2023 | View on chart |
| DXCM | ▲ Buy | Grant | 994 | $1 | 5/20/2022 | View on chart |
| DXCM | ▼ Sell | Other | 918 | $0 | 5/19/2022 | View on chart |
| DXCM | ▼ Sell | Other | 918 | $0 | 5/19/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 100 | $44K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $89K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $88K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 476 | $210K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,147 | $498K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 443 | $196K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 400 | $178K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $89K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 400 | $180K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $90K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 200 | $90K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 400 | $181K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 100 | $43K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 100 | $43K | 2/10/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 100 | $44K | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM
The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.